Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Alps Group (Nasdaq:ALPS) received a Nasdaq notice on May 15, 2026 for not meeting the $1.00 minimum bid price requirement after 30 consecutive business days below this level.
Rhea-AI Summary
Alps Group (Nasdaq:ALPS) received a Nasdaq notice on May 15, 2026 for not meeting the $1.00 minimum bid price requirement after 30 consecutive business days below this level.
The notice has no immediate impact on listing, trading, operations, or financial condition. Alps has 180 days, until November 11, 2026, to regain compliance and may qualify for an additional 180 days, but faces potential delisting if the deficiency is not cured.
Positive
- No immediate impact on Nasdaq listing, trading, operations, or financial condition
- Initial 180-day compliance period until November 11, 2026
- Potential additional 180-day period if other listing standards are met
- Company is evaluating options to regain Nasdaq bid price compliance
Negative
- Currently non-compliant with Nasdaq $1.00 minimum bid price rule 5450(a)(1)
- Risk of Nasdaq delisting if bid price deficiency is not cured
- Possible need for a reverse stock split to restore bid price compliance
- No assurance the company will regain or maintain Nasdaq listing compliance
Details
News Market Reaction – ALPS
In the May 20 session, ALPS declined 11.36%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Nasdaq minimum bid
- $1.00 per share
- Nasdaq Listing Rules 5450(a)(1) continued listing requirement
- Compliance look-back period
- 30 consecutive business days
- Period over which bid price was below $1.00
- Initial compliance period
- 180 calendar days
- Period granted to regain Nasdaq bid-price compliance
- Potential second period
- Additional 180 calendar days
- Possible extension if other listing standards are met
- Compliance deadline
- November 11, 2026
- End of initial Nasdaq compliance period
- Current share price
- $0.85
- Price before announcement; below $1.00 Nasdaq threshold
- 52-week high
- $2.90
- Reference for longer-term price compression
- 52-week low
- $0.0159
- Current price is far above the 52-week low
Historical Context
-
Independent ex-EY partner added to board and key committees.
-
Published safety and tolerability data for autologous NK cell infusions.
-
Announced potential exosome pipeline expansion beyond CELESOME(+).
-
Named new CFO with extensive finance and accounting experience.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rules 5450(a)(1) regulatory
minimum bid price regulatory
reverse stock split financial
delisting regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced that on May 15, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of
The notification has no immediate effect on the listing or trading of the Company’s ordinary shares on Nasdaq, and it does not affect the Company’s current business operations or financial condition. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until November 11, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting.
The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance, there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
About Alps Group
Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. Alps Group’s mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible and affordable.
Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor Relations Contact
Philip Carlson
KCSA Strategic Communications
212-896-1233
alps@kcsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.